News

Public · Published

Cantor Fitzgerald maintains AbbVie at Overweight, raises price target to $325 from $290

Cantor Fitzgerald maintained its Overweight rating on AbbVie and raised its price target to $325 from $290, a 12.1% increase. The target implies 10.2% upside from AbbVie's October 30 closing price of $294.89. Five recent analyst targets ranged from $275 to $325.

Published:

Updated:

What happened

Cantor Fitzgerald maintained its Overweight rating on AbbVie and raised its price target to $325 from $290, a 12.1% increase. The target implies 10.2% upside from AbbVie’s October 30 closing price of $294.89. Five recent analyst targets ranged from $275 to $325.

Confirmed

Global impact / market context

The higher target signals that Cantor Fitzgerald sees more potential value in AbbVie shares than before, but it is an analyst estimate rather than a guaranteed outcome. If investors act on the more favorable view, their buying or selling could influence the share price; the article reports no market reaction.

Analyst inference

Recent analyst views are not uniform: the five targets listed span $275 to $325, while ratings include Neutral, Overweight, Outperform and Buy. That spread shows differing expectations about AbbVie’s value; the article provides no company results or industry developments explaining the gap.

Confirmed

What to watch

  1. Whether other analysts change their AbbVie ratings or price targets, since the article’s five recent targets span $275 to $325 and reflect different views. Analyst inference
  2. Whether AbbVie’s share price moves toward or away from Cantor Fitzgerald’s $325 target; the article gives a prior close but no subsequent price reaction. Analyst inference
  3. The article provides no explanation for Cantor Fitzgerald’s higher target, so any stated reasons in later coverage would clarify what assumptions support its view. Analyst inference

Evidence

  • Original source link unavailable